ES2090432T3 - Preparaciones farmaceuticas con una modificacion cristalina especial del ester isopropil-(2-metoxietilico) del acido 1,4-dihidro-2,6-dimetil-4-(3-nitrofenil)-3,5-piridincarboxilico. - Google Patents

Preparaciones farmaceuticas con una modificacion cristalina especial del ester isopropil-(2-metoxietilico) del acido 1,4-dihidro-2,6-dimetil-4-(3-nitrofenil)-3,5-piridincarboxilico.

Info

Publication number
ES2090432T3
ES2090432T3 ES92114835T ES92114835T ES2090432T3 ES 2090432 T3 ES2090432 T3 ES 2090432T3 ES 92114835 T ES92114835 T ES 92114835T ES 92114835 T ES92114835 T ES 92114835T ES 2090432 T3 ES2090432 T3 ES 2090432T3
Authority
ES
Spain
Prior art keywords
ester
pharmaceutical preparations
piridincarboxilico
metoxietilico
nitrofenil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92114835T
Other languages
English (en)
Inventor
Alfons Dr Grunenberg
Ahmed Dr Hegasy
Wolfgang Dr Muck
Gerhard Dr Franckowiak
Rango-Rao Dr Kanikanti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Application granted granted Critical
Publication of ES2090432T3 publication Critical patent/ES2090432T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA INVENCION SE REFIERE A PREPARACIONES FARMACEUTICAS, QUE CONTIENEN UNA MODIFICACION CRISTALINA ESPECIAL DEL ESTER 1,4 DIHIDRO ACIDO DICARBOXILICO PARA SU FABRICACION.
ES92114835T 1991-09-11 1992-08-31 Preparaciones farmaceuticas con una modificacion cristalina especial del ester isopropil-(2-metoxietilico) del acido 1,4-dihidro-2,6-dimetil-4-(3-nitrofenil)-3,5-piridincarboxilico. Expired - Lifetime ES2090432T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4130173A DE4130173A1 (de) 1991-09-11 1991-09-11 Pharmazeutische zubereitungen mit einer speziellen kristallmodifikation des 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridindicarbonsaeure-isopropyl-(2-methoxyethyl)-esters

Publications (1)

Publication Number Publication Date
ES2090432T3 true ES2090432T3 (es) 1996-10-16

Family

ID=6440342

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92114835T Expired - Lifetime ES2090432T3 (es) 1991-09-11 1992-08-31 Preparaciones farmaceuticas con una modificacion cristalina especial del ester isopropil-(2-metoxietilico) del acido 1,4-dihidro-2,6-dimetil-4-(3-nitrofenil)-3,5-piridincarboxilico.

Country Status (11)

Country Link
US (1) US5599824A (es)
EP (1) EP0531845B1 (es)
JP (1) JPH05229945A (es)
AT (1) ATE141052T1 (es)
CA (1) CA2077704C (es)
DE (2) DE4130173A1 (es)
DK (1) DK0531845T3 (es)
ES (1) ES2090432T3 (es)
GR (1) GR3020962T3 (es)
HK (1) HK41697A (es)
MX (1) MX9205077A (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6287693B1 (en) * 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
ES2340422T3 (es) 2003-06-13 2010-06-02 Skendi Finance, Ltd. Microparticulas constituidas por estradiol y colesterol.
CN1824647B (zh) * 2005-02-22 2011-04-20 田边三菱制药株式会社 (±)2-(二甲基氨基)-1-{[O-(m-甲氧基苯乙基)苯氧基]甲基}乙基氢琥珀酸酯盐酸盐的晶体
US9399019B2 (en) 2012-05-09 2016-07-26 Evonik Corporation Polymorph compositions, methods of making, and uses thereof
US20180098977A1 (en) * 2016-08-23 2018-04-12 Edge Therapeutics, Inc. Scalable microparticulate formulations containing polymorphic nimodipine form 2 prepared by a solvent evaporation process
WO2019018306A1 (en) * 2017-07-17 2019-01-24 Edge Therapeutics, Inc. ADVANCED MICROPARTICULAR FORMULATIONS CONTAINING FORM 2 OF MICRONIZED POLYMORPHIC NIMODIPINE
USD867911S1 (en) * 2018-10-10 2019-11-26 Adel J M S Alabdin Combination gas leak sensor and communication device

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932645A (en) * 1971-04-10 1976-01-13 Farbenfabriken Bayer Ag Pharmaceutical compositions containing unsymmetrical esters of 1,4-dihydropyridine 3,5-dicarboxylic acid
DE2815578C2 (de) * 1978-04-11 1986-01-16 Bayer Ag, 5090 Leverkusen Neue pharmazeutische Verwendung von Nimodipin
DE3033919A1 (de) * 1980-09-09 1982-04-22 Bayer Ag, 5090 Leverkusen Feste arzneizubereitungen enthaltend nifedipin und verfahren zu ihrer herstellung
DE3318649A1 (de) * 1983-05-21 1984-11-22 Bayer Ag, 5090 Leverkusen Zweiphasenformulierung
DE3424553A1 (de) * 1984-07-04 1986-01-09 Bayer Ag, 5090 Leverkusen Feste arzneizubereitungen mit dihydropyridinen und verfahren zu ihrer herstellung
GB8729471D0 (en) * 1987-12-17 1988-02-03 Wyeth John & Brother Ltd New crystal form

Also Published As

Publication number Publication date
DK0531845T3 (da) 1996-11-25
DE59206868D1 (de) 1996-09-12
DE4130173A1 (de) 1993-03-18
CA2077704C (en) 2003-03-11
EP0531845A1 (de) 1993-03-17
US5599824A (en) 1997-02-04
EP0531845B1 (de) 1996-08-07
JPH05229945A (ja) 1993-09-07
CA2077704A1 (en) 1993-03-12
HK41697A (en) 1997-04-11
MX9205077A (es) 1993-03-01
ATE141052T1 (de) 1996-08-15
GR3020962T3 (en) 1996-12-31

Similar Documents

Publication Publication Date Title
HN1997000110A (es) Derivados del acido arilsulfoonilamino hidroxamico
ES2156156T3 (es) Compuesto terapeutico - conjugados de acidos grasos.
ES2084073T3 (es) Aclarados finales libres de cromo para metal fosfatado.
ES2098140T3 (es) Liosferas que contienen gonadotropina.
ES2189782T3 (es) Derivados de pteridina opticamente activos.
HN1999000131A (es) Derivados del acido hidroxi pipecolato hidroxamico.
ES544852A0 (es) Un procedimiento para la preparacion de derivados sustituidos ester benzoato de 3-hidroximorfinanos.
EP0602586A3 (es)
DE3669882D1 (de) 2-zyanakrylsaeureester enthaltende zusammensetzung.
PL309282A1 (en) Application of 2-amino-6-n-propyl-amino- 4,5,6,7-tetrahydrobenzothiasole (pramipexol) as an antidepressant
IT1214189B (it) Vino a basso tenore alcolico. procedimento per la produzione di
MX9200216A (es) Procedimiento para la preparacion de anhidrido de acido malonico.
ES553653A0 (es) Un procedimiento para la preparacion de una composicion detergente que incluye un ester de acido fosforico.
MX171542B (es) Composiciones farmaceuticas que contienen deoxirribonucleosidos para cicatrizacion de heridas
AU2142183A (en) 1:-ethoxycarbonyloxyethyl ester of valproic acid
UA10208A (uk) Дерматологічний косметичний засіб
CA2141563A1 (en) Novel 2-Substituted Indane-2-Mercaptoacetylamide Tricyclic Derivatives Useful as Inhibitors of Enkephalinase
IT8421068A0 (it) Derivati di acido poliidrossibenzoico ad azione farmaceutica.
ITRM910430A1 (it) Composizioni farmaceutiche di somatostatina con assorbimento migliorato, loro preparazione e loro impiego
ES2075454T3 (es) Forma cristalina pura de rifapentina.
ES2130548T3 (es) Nuevos derivados alquil-amino-indanos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
IT8521000A0 (it) Composizione farmaceutica per applicazioni topiche per la cessione graduale di iodio.
MY105851A (en) Sugar ester as detergency boosters
FI962264A7 (fi) Tulehduksia aiheuttavan sytokiinin muodostumisen inhibiittori, joka käsittää polyprenyylin johdannaisia aktiivisena ainesosana
ES2184150T3 (es) Uso de derivados de los acidos 7-(1-aminometil-2-oxa-7-aza-biciclo(3.3.0)oct-7il)-quinoloncarboxilico y -naftiridoncarboxilico para el tratamiento de infecciones causadas por helicobacter pylori y de las afecciones gastroduodenales asociadas con ellas.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 531845

Country of ref document: ES

FG2A Definitive protection

Ref document number: 531845

Country of ref document: ES